Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Table 4 Indicators of bone formation and soft tissue turnover

MARKER	Parkinson 2003[15]Φ baseline	Parkinson 2003[15]Φ At IGF-1 normalisation	P v. baseline	Fairfield 2002[10]ΦΦ placebo 12 wks	Fairfield 2002[10]ΦΦPEG 12 wks	P v. placebo
*Bone formation*
osteocalcin	47^θ (14 - 109)	21 (10 - 73)	< 0.001	+0.01^θθ (0.39)	-2.2 (0.44)	0.009
terminal propeptide procollagen I	70^θ (12)	38 (8)	< 0.01	+18.1^θ (12.8)	-23.6 (9.6)	0.022
bone alkaline phosphatase	147^θθθ (29)	120 (23)	< 0.05
*Bone resorption*
cross linked telopeptide of collagen I	0.8^Ψ (0.2 - 2.4)	0.4 (.03 - 1.3)	<0.0001	+1^θθ (0.3)	-4.4 (1.4)	0.024
urinary ratio cross linked telopeptide/creatinine	92^θθθ	56 (14)	< 0.01
*Soft tissue formation*
terminal propeptide of procollagen III	4.3^θ (0.3)	3.1 (0.3)	<0.01

Φ data are mean (SEM) or median (range); ΦΦ data are mean (SEM); θ ug/L; θθ nmol/L; θθθ units unclear. Ψ pmol/L.

ISSN: 1472-6823